- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- July 2022
- 199 Pages
Global
From €3079EUR$3,185USD£2,645GBP
€4399EUR$4,550USD£3,778GBP
- Report
- April 2023
- 112 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- May 2023
- 140 Pages
Global
From €5800EUR$5,999USD£4,982GBP
Adriamycin (doxorubicin) is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a type of anthracycline antibiotic, derived from Streptomyces bacteria, and works by interfering with the growth of cancer cells. Adriamycin is administered intravenously and is often used in combination with other drugs to treat lung cancer. It is also used to treat other types of cancer, such as breast, ovarian, and bladder cancer.
Adriamycin is a widely used drug in the treatment of lung cancer, and is often used in combination with other drugs to maximize its effectiveness. It is generally well tolerated, although it can cause side effects such as nausea, vomiting, hair loss, and fatigue. It is also associated with an increased risk of heart damage, so patients must be monitored closely for any signs of cardiac toxicity.
Some companies in the Adriamycin market include Pfizer, Bristol-Myers Squibb, and Merck. Show Less Read more